Optometry

Editor's Choice

Besifloxacin ophthalmic suspension 0.6% is approved for bacterial conjunctivitis

Besifloxacin ophthalmic suspension 0.6% (Besivance, Bausch & Lomb) was approved recently by the FDA for the treatment of bacterial conjunctivitis. Besifloxacin suspension is able to fight bacteria that are growing resistant to older anti-infectives.

LATEST ARTICLES

San Francisco unmatched as a travel destination

San Francisco is nearly synonymous with a high cost of living. The advent and financial success of the early years of the Internet revolution still lures high-income folks to the city by the bay. Property values and household income are among the top in the nation, which enables a profitable restaurant and entertainment scene.

Besifloxacin: Fluoroquinolone developed expressly for ophthalmic use

Besifloxacin is the first chlorinated fluoroquinolone developed especially for use in the eye.

Diabetic macular edema responds to ranibizumab in study

Diabetic macular edema responds to treatment with ranibizumab (Lucentis, Genentech), according to results of the RESOLVE study. The patient responses to the drug in the changes in the visual acuity and central macular thickness were significantly better in the groups treated with two concentrations of ranibizumab compared with the sham-treated group.

Dining: Please your appetite in Bay City

San Francisco has cuisine to satisfy many taste buds. From dim sum to gnocchi, use this guide to map out your dining tour of the city by the bay.

Kill kinetics of advanced-generation fluoroquinolones compared in study

An in vitro kill kinetics study evaluated eradication of 18 human ocular Staphylococcus isolates by commercial formulations of gatifloxacin 0.3% (Zymar, Allergan) and moxifloxacin 0.5% (Vigamox, Alcon Laboratories). Gatifloxacin demonstrated superior activity, which may be attributed to the presence of benzalkonium chloride 0.005% in its formulation.